Genialis' krasID is an RNA-based biomarker that uses machine learning to model fundamental aspects of KRAS cancer biology to predict tumor response to and clinical benefit of KRAS inhibitors.
Researchers develop a liquid biopsy test able to distinguish between different types of lung cancer, improving diagnosis and treatment.
Under an expanded program, more MassMutual policy holders will be offered saliva-based tests from Genomics that generate polygenic risk scores for nine common preventable conditions.
An artificial intelligence generated model of the infant gut microbiome can help predict developmental risks at an early stage.
Researchers at Stanford Medicine say that immune cells in the lungs known as interstitial macrophages are critical in the development of severe--and potentially deadly--COVID.
Genetic testing could determine which young breast cancer survivors are at highest risk of a second, new breast cancer and thus help others avoid unnecessary treatment.
In a comprehensive study spanning three Scandinavian countries, researchers from the Karolinska Institute in Sweden have found no significant link between the use of GLP-1 analogues, a popular class of diabetes drugs, and an increased risk of thyroid cancer.
A genetic variant in the fibronectin 1 gene conveys significant protection against Alzheimer's disease in high risk APOE4 homozygotes.
More than half of cancer drugs granted accelerated approval between 2013 and 2017 did not demonstrate a significant improvement in overall survival (OS) or quality of life (QoL) within five years of approval, shows an analysis of U.S. Food and Drug Administration (FDA) data.
Saruparib showed favorable safety profile over first-generation PARP inhibitors in Phase I/II trial.
